Clinical Trial Detail

NCT ID NCT02504892
Title Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

kidney cancer

Therapies

Everolimus

Age Groups: adult

No variant requirements are available.